AUMdb
OM

Opaleye Management Inc.

SEC-registered Private Fund Manager · Small ($100M–$1B) CRD 124513 · SEC file 801-78700 · Boston, MA
☆ Save with Pro ADV data as of Feb 19, 2026
Regulatory AUM
$803M
Discretionary
$803M
Clients
2
Avg AUM / client
$401M
Accounts
2
Employees
4

AUM over time

$116M $833M
Oct 2013 Dec 2025

Annual snapshots from Form ADV filings · as of Feb 19, 2026

Investments (13F portfolio — 54 positions, $759,221,131)

13F period Mar 31, 2026
#IssuerClassValueShares% of 13F% of AUM
1 Harrow Inc COM $99,864,430 2,832,230 13.2% 12.4%
2 Liquidia Corporation COM NEW $88,820,500 2,545,000 11.7% 11.1%
3 Eton Pharmaceuticals Inc COM $70,584,800 2,860,000 9.3% 8.79%
4 Sol Gel Technologies Ltd SHS NEW $39,610,000 500,000 5.22% 4.93%
5 Rhythm Pharmaceuticals Inc COM $35,323,200 123,000 4.65% 4.4%
6 Apogee Therapeutics Inc COM $32,826,300 390,000 4.32% 4.09%
7 Disc Medicine Inc COM $26,918,740 421,000 3.55% 3.35%
8 Urogen Pharma Ltd COM $25,711,400 1,430,000 3.39% 3.2%
9 Crescent Biopharma Inc. COM $24,112,738 1,312,615 3.18% 3.0%
10 Stoke Therapeutics Inc COM $22,792,000 700,000 3.0% 2.84%
11 Perspective Therapeutics Inc COM NEW $19,494,750 4,675,000 2.57% 2.43%
12 Rezolute Inc COM NEW $19,215,000 6,300,000 2.53% 2.39%
13 Meiragtx Hldgs Plc COM $18,387,423 2,123,259 2.42% 2.29%
14 Tg Therapeutics Inc COM $17,772,700 535,000 2.34% 2.21%
15 Sanuwave Health Inc COM $16,966,106 981,267 2.23% 2.11%
16 Edgewise Therapeutics Inc COM $15,750,000 500,000 2.07% 1.96%
17 Alpha Cognition Inc COM NEW $14,065,106 2,561,950 1.85% 1.75%
18 Annexon Inc COM $12,917,956 2,331,761 1.7% 1.61%
19 Alumis Inc COM $12,116,500 550,000 1.6% 1.51%
20 Codexis Inc COM $11,059,550 6,785,000 1.46% 1.38%
21 Protagonist Therapeutics Inc COM $10,540,000 100,000 1.39% 1.31%
22 Revolution Medicines Inc COM $9,725,000 100,000 1.28% 1.21%
23 Xoma Royalty Corporation COM NEW $9,411,000 300,000 1.24% 1.17%
24 Q32 Bio Inc COM $8,064,984 1,256,228 1.06% 1.0%
25 Mbx Biosciences Inc COM $7,761,000 260,000 1.02% 0.97%

Top 25 of 54 positions from the manager's latest Form 13F · source filing (EDGAR) ↗. 13F covers long US-listed positions only. "% of AUM" is share of the firm's total regulatory AUM (Form ADV Item 5.F).

Who they serve

Client typeClientsAUM% of AUM
Pooled investment vehicles (non-investment companies) 1 $789M 98.3%
Corporations and other businesses 1 $13.6M 1.69%

Private funds (1)

Reported in Form ADV Section 7.B.(1), filing of Mar 2024 · $422M combined gross assets

FundTypeDomicileGross assetsOwners
Opaleye, L.P. Hedge Fund Delaware $422M 63

People (1)

NameRole / titleCredentialsWith firm sinceOwnership
Silverman, James, Aaron President/Chief Compliance Officer Feb 1996 (31y) 75% or more

Undisclosed: 0% – 25% of the firm is not attributable from the filed Schedule A bands.

Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.

Private funds (1, $422M gross assets)

FundTypeGross assetsMin. investmentOwners
Opaleye, L.P. Hedge Fund $422M $300K 63

From Form ADV Section 7.B private fund reporting.

Documents (1 archived)

FormPeriodSize
Form ADV (full filing) 02/19/2026 1.28 MB View · PDF · Source ↗

Archived copies of the firm's regulatory filings, versioned by content hash.

Disciplinary disclosures

Regulatory · Item 11.D(4) as of Mar 26, 2024

Allegations: AN ADMINISTRATIVE COMPLAINT WAS BROUGHT ON MARCH 9, 2011 AGAINST JAMES A. SILVERMAN, RISK REWARD CAPITAL MANAGEMENT CORP., RRC MANAGEMENT, LLC AND RRC BIO FUND, LP ("RESPONDENTS") BY THE ENFORCEMENT SECTION OF THE MASSACHUSETTS SECURITIES DIVISION OF THE OFFICE OF THE SECRETARY OF THE COMMONWEALTH ("DIVISION"). THESE ENTITIES ARE NOW KNOWN AS OPALEYE MANAGEMENT INC., OPALEYE GP LLC AND OPALEYE, L.P. RESPECTIVELY. IN THE COMPLAINT, THE DIVISION ALLEGED A LACK OF PROCEDURES REGARDING MATERIAL NON-PUBLIC INFORMATION AND NON-COMPLIANCE WITH RESPECT TO MAINTENANCE OF BOOKS AND RECORDS. ON SEPTEMBER 24, 2014, THE PARTIES ENTERED INTO A CONSENT ORDER WHEREIN THEY AGREED TO SETTLE THE MATTER. RESPONDENTS NEITHER ADMITTED NOR DENIED THE ALLEGATIONS CONTAINED IN THE ORIGINAL COMPLAINT. Status: Final Sanction Detail: RESPONDENTS JOINTLY AND SEVERALLY PAID A FINE OF $50,000 ON OCTOBER 1, 2014. Summary: ON SEPTEMBER 24, 2014 , OPALEYE MANAGEMENT INC., OPALEYE GP LLC AND OPALEYE, L.P. ENTERED INTO A CONSENT ORDER ("ORDER") WHEREIN THEY AGREED TO SETTLE THIS MATTER. RESPONDENTS NEITHER ADMITTED NOR DENIED THE ALLEGATIONS CONTAINED IN THE ORIGINAL COMPLAINT. THE ORDER REQUIRED RESPONDENTS TO COMPLY WITH 203(A) AND 203A OF THE MASSACHUSETTS ACT AND MASSACHUSETTTS REGULATIONS, THAT RESPONDENTS VERIFY THAT BETWEEN OCTOBER 29, 2011 AND OCTOBER 29, 2013 THAT RESPONDENTS DID NOT USE ANY MATCHING OR EXPERT NETWORK SERVICES AND THAT THE RESPONDENTS PAY A FINE OF $50,000. THE ORDER DID NOT CONTAIN OR CONSTITUTE ANY LEGAL OR FACTUAL FINDINGS OR CONCLUSION, INCLUDING WITHOUT LIMITATION, ANY FINDING OF ANY VIOLATION OR LAW OR REGULATION THAT PROHIBITS FRAUDULENT, MANIPULATIVE OR DECEPTIVE CONDUCT AND PROVIDES NO STATUTORY DISQUALIFICATION.

Disclosure text reproduced verbatim from the firm's own Form ADV filings.

How they charge

  • Percentage of assets under management
  • Performance-based fees

Services

  • Portfolio management for pooled investment vehicles
  • Portfolio management for businesses/institutional clients

Custody

Reported custodians

Amounts as reported in ADV Item 5.K.(3) (custodians holding 10%+ of SMA assets).

Firm reports having custody of client funds or securities (Item 9.A).

Source

All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Feb 19, 2026.

View current Form ADV (SEC/IAPD) ↗